Extrapulmonary manifestations of SARS-CoV-2: a new coronavirus infectionas an aggravating factor in peptic ulcer disease
https://doi.org/10.31146/1682-8658-ecg-199-3-134-142
Abstract
The global pandemic of the new coronavirus infection (COVID-19) has become an extreme challenge for the health care of the whole world since 2020.
The main target of the SARS-CoV-2 virus is the lungs, but at the same time, more and more evidence is accumulating that the new coronavirus can also aff ect other organs and systems, such as the heart, blood vessels, kidneys, intestines, and brain.
Thus, adequate management of a coronavirus patient means not only the therapy of viral pneumonia, but also the timely diagnosis and treatment of damage to other organs.
The analysis of predictor factors of severe course and fatal outcome in COVID-19 indicates the aggravating role of comorbid pathology, such as cardiovascular diseases, diabetes mellitus, chronic obstructive pulmonary disease, chronic gastrointestinal diseases. Therefore, in addition to measures to prevent infection with SARS-CoV-2, measures should also be taken to control the comorbid conditions present in the patient.
ACE2 receptors, which the virus uses to penetrate human cells, can also be expressed in the esophagus, stomach, small and large intestines, liver and pancreas. This makes the frequency of gastroenterological symptoms in COVID-19 high, which is caused both by the defeat of the digestive organs by the coronavirus itself and by the exacerbation of chronic gastrointestinal diseases against the background of infection and its aggressive therapy. At the same time, the presence and severity of digestive diseases signifi cantly affect the clinical course of COVID-19.
This article is devoted to the pathogenesis, clinical picture, approaches to the diagnosis and therapy of erosive ulcerative lesions of the stomach and duodenum against the background of a new coronavirus infection.
About the Authors
B. N. Levitan
Astrakhan State Medical University
Russian Federation
Russian Federation
Boleslav N. Levitan - Head of the Department of Faculty Therapy, MD, Professor; Scopus ID: 7003706105.
121, Bakinskaya St., Astrakhan, 414000
V. V. Skvortsov
Volgograd State Medical University
Russian Federation
Russian Federation
Vsevolod V. Skvortsov - Associate Professor of the Department of Internal Diseases, MD.
1, Pavshikh Bortsov sq., Volgograd, 400131
N. V. Eremenko
Volgograd State Medical University
Russian Federation
Russian Federation
Natalia V. Eremenko - 6th year student of the Faculty of General Medicine.
1, Pavshikh Bortsov sq., Volgograd, 400131
References
1. Temporary guidelines of the Ministry of Health of the Russian Federation. Prevention, diagnosis and treatment of new coronavirus infection (COVID-19). Moscow. Version 14 (27/12/2021), 232 p. (in Russ).
2. Grinevich V. B., Gubonina I. V., Doshchitsin V. L., et al. Management of patients with comorbidity during novel coronavirus (COVID-19) pandemic. National Consensus Statement 2020. Cardiovascular Th erapy and Prevention. 2020;19(4):2630. (In Russ.) doi:10.15829/1728–8800–2020–2630
3. Butov M. A., Vasilevskaya A. S., Shelukhina S. V., et al. Functional gastrointestinal diseases and the COVID-19 pandemic: the view of an outpatient gastroenterologist. Experimental and Clinical Gastroenterology. 2021;(2):27- 31. (in Russ.) doi:10.31146/1682–8658-ecg-186–2–27-31
4. Grinevich V. B., Kravchuk Yu. A., Ped V. I., et al. Management of patients with digestive diseases during the COVID-19 pandemic: Clinical Practice Guidelines by the Gastroenterological Scientific Society of Russia. Experimental and Clinical Gastroenterology. 2020;179(7): 4–51. (in Russ.) doi: 10.31146/1682–8658-ecg-179–7-4–51
5. Stefanyuk O. V., Lazebnik L. B. Th e defeat of the digestive system during infection SARS-CoV-2. Experimental and Clinical Gastroenterology.2020;175(3): 4–9. (In Russ.) doi: 10.31146/1682–8658-ecg-175–3–4–9
6. Wong S. H., Lui R. N., Sung J. J. Covid-19 and the digestive system, J. Gastroenterol. Hepatol. 2020;35(5):744– 748. doi: 10.1111/jgh.15047
7. Du M., Cai G., Chen F., et al. Multiomics Evaluation of Gastrointestinal and Other Clinical Characteristics of COVID-19. Gastroenterology. 2020;158:2298–2301. e2297. doi: 10.1053/j.gastro.2020.03.045
8. Ivashkin V. T., Sheptulin A. A., Zolnikova O. Yu., et al. New Coronavirus Infection (COVID-19) and Digestive System. Russian Journal of Gastroenterology, Hepatology, Coloproctology. 2020;30(2):3–7. (In Russ.) doi: 10.22416/1382–4376–2020–30–3–7
9. Yakovenko E. P., Iakovenko A. V., Ivanov A. N., Agafonova N. A. Pathology of the digestive tract and liver with COVID-19. Experimental and Clinical Gastroenterology. 2020;176(4): 19–23. (In Russ.) doi: 10.31146/1682–8658-ecg-176–4–19–23
10. Xiao F., Tang M., Zheng X., et al. Evidence for Gastrointestinal Infection of SARS-CoV-2. Gastroenterology. 2020;158(6):1831–1833.e3. doi:10.1053/j.gastro.2020.02.055
11. Zhang Y., Geng X., Tan Y., et al. New understanding of the damage of SARS-CoV-2 infection outside the respiratory system. Biomed. Pharmacother. 2020;127:110195. doi: 10.1016/j.biopha.2020.110195
12. Sultan S., Altayar O., Siddique S. M., et al. AGA Institute rapid review of the gastrointestinal and liver manifestations of COVID-19, meta-analysis of international data, and recommendations for the consultative management of patients with COVID-19. Gastroenterology. 2020;159(1):320–334.e27. doi:10.1053/j.gastro.2020.05.001
13. Zhang H., Kang Z., Gong H., et al. Digestive system is a potential route of COVID-19: an analysis of single-cell coexpression pattern of key proteins in viral entry process. Gut 2020;69:1010–8.
14. Wong M. C., Huang J., Lai C., et al. Detection of SARSCoV-2 RNA in fecal specimens of patients with confi rmed COVID-19: a meta-analysis. J Infect 2020;81: e31–8. 2020;81(2): e31-e38. doi: 10.1016/j.jinf.2020.06.012
15. Deb A., Th ongtan T., Costilla V. Gastric ulcerations in COVID-19: an ominous sign? BMJ Case Rep. 2021;14: e244059. doi:10.1136/bcr-2021–244059
16. Cardinale V., Capurso G., Ianiro G., et al. Intestinal permeability changes with bacterial translocation as key events modulating systemic host immune response to SARS-CoV-2: a working hypothesis. Dig Liver Dis 2020;52:1383–9
17. Zhang H., Shao B., Dang Q., et al. Pathogenesis and Mechanism of Gastrointestinal Infection With COVID-19. Front. Immunol. 2021;12:674074. doi:10.3389/fimmu.2021.674074
18. Ivashkin V. T., Maev I. V., Tsar’kov P.V., et al. Diagnosis and Treatment of Peptic Ulcer in Adults (Clinical Guidelines of the Russian Gastroenterological Association, the Russian Society of Colorectal Surgeons and the Russian Endoscopic Society). Russian Journal of Gastroenterology, Hepatology, Coloproctology. 2020;30(1):49–70. (in Russ.) doi:10.22416/1382–4376–2020–30–1–49–70
19. Mao R., Qui Y., He J-S., et al. Manifestations and prognosis of gastrointestinal and liver involvement in patients with COVID-19: a systematic review and meta- analysis. Lancet Gastroenterol Hepatol. 2020;5(7):667-678. doi:10.1016/S2468–1253(20)30126–6
20. Martin T. A., Wan D. W., Hajifathalian K., et al. Gastrointestinal Bleeding in Patients With Coronavirus Disease 2019: A Matched Case- Control Study. Am J Gastroenterol. 2020;115(10):1609–1616. doi:10.14309/ajg.0000000000000805
21. Sharma S., Kumar R., Shalimar. Management of Gastrointestinal Bleeding in Coronavirus Disease: Exploring the Options. Am J Gastro enterol. 2021;116(4):843–844. doi:10.14309/ajg.0000000000000979
22. Tian Y, Rong L, Nian W, He Y. Review article: gastrointestinal features in COVID-19 and the possibility of faecal transmission. Aliment Pharmacol Ther 2020;51(9):843–51. doi: 10.1111/apt.15731
23. Melazzini F., Lenti M. V., Mauro A,. et al. Peptic ulcer disease as a common cause of bleeding in patients with coronavirus disease 2019. Am J Gastroenterol. 2020. 1;115(7):1139–1140. doi: 10.14309/ajg.0000000000000710
24. Mauro A., De Grazia F., Lenti M. V., et al. Upper gastrointestinal bleeding in COVID-19 in patients: Incidence and management in a multicenter experience from Northern Italy. Clin Res Hepatol Gastroenterol. 2021;45(3):101521. doi:10.1016/j.clinre.2020.07.025
25. Trindade A. J., Izard S., Coppa K. Gastrointestinal bleeding in hospitalized COVID-19 patients: a propensity score matched cohort study. J Intern Med. 2021; 289(6):887-894. doi: 10.1111/joim.13232
26. Rizvi A., Patel Z., Liu Y., et al. Gastrointestinal Sequelae 3 and 6 Months After Hospitalization for Corona virus Disease 2019. Clin Gastroenterol Hepatol. 2021;19(11):2438–2440.e1. doi:10.1016/j.cgh.2021.06.046
27. Galvez A., King K., El Chaar M., Claros L. Perforated marginal ulcer in a COVID-19 patient laparoscopy in these trying times? Obes Surg. 2020;30(11):4605–4608. doi: 10.1007/s11695–020–04709–8
28. He L., Zhao W., Zhou W., et al. An emergency surgery in severe case infected by COVID-19 with perforated duodenal bulb ulcer. Ann Surg. 2020 Jul;272(1): e35-e37. doi: 10.1097/SLA.0000000000003958
29. Zhou F., Yu T., Du R., et al. Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. Lancet. 2020. 28;395(10229):1054–1062. doi: 10.1016/S0140–6736(20)30566–3
30. Kangas-D ick А., PrienC., Rojas K., et al. Gastrointestinal perforation in a critically ill patient with COVID-19 pneumonia. SAGE Open Med Case Rep. 2020 16;8:2050313X20940570. doi: 10.1177/2050313X20940570
31. Merdad G. A., Seadawi L. E., Mustafa A. A. Peptic ulcer associated with COVID-19 in Saudi Arabia. Saudi Med J. 2021;42(9):1036–1040. doi:10.15537/smj.2021.42.9.20210224
32. Mahadev S., Aroniadis O. S., Barraza L., et al. Impact of the COVID-19 pandemic on endoscopy practice: results of a cross- sectional survey from the New York metropolitan area. Gastrointest Endosc. 2020. doi:10.1016/j.gie.2020.04.047
33. Trukhan D. I., Degovtsov E. N., Mazurov A. L. Choice of protonic pump inhibitor with regard to multimorbidity: a focus on rabeprazol. Meditsinsky Sovet. 2019; 3: 34–42. (in Russ.) doi: 10.21518/2079–701X-2019–3–34–42
34. Moayyedi P., Eikelboom J. W., Bosch J., et al. Pantoprazole to Prevent Gastroduodenal Events in Patients Receiving Rivaroxaban and/or Aspirin in a Randomized, Double- Blind, Placebo-C ontrolled Trial. Gastroenterology. 2019;157(2):403–412.e5. doi: 10.1053/j.gastro.2019.04.041
35. Levitan B. N., Skvortsov V. V., Samokhvalova P. D. Modern approaches in treatment of helicobacteriosis in patients with peptic ulcer. Medical alphabet. 2021; (40): 7-13. (in Russ.) doi: 10.33667/2078–5631–2021–40–7-13
Review
For citations:
Levitan B.N., Skvortsov V.V., Eremenko N.V. Extrapulmonary manifestations of SARS-CoV-2: a new coronavirus infectionas an aggravating factor in peptic ulcer disease. Experimental and Clinical Gastroenterology. 2022;(3):134-142. (In Russ.) https://doi.org/10.31146/1682-8658-ecg-199-3-134-142
Views:
842
Email this article 